We present the case report of a patient who manifested seizures due to malingering, and discuss the differential diagnosis. The characteristics typical of nonepileptic seizures not due to malingering and of seizures due to malingering are described. Methods of distinguishing nonepileptic seizures from epileptic seizures are outlined, and the differences between seizures due to malingering and other nonepileptic seizures are discussed.

The study presented was conducted to analyze the effects of obsessive-compulsive symptoms on patients' quality of life and the costs incurred by patients and society for the treatment of obsessive-compulsive disorder (OCD). To accomplish this, a detailed 410-item questionnaire of psychosocial function and economic cost was sent to every fourth member of the Obsessive Compulsive Foundation. Of the 2,670 members who received the survey, 701 (26.9%) returned it.

Outcome measures included symptomatology, course of illness, impact of illness on psychosocial and other functioning, effects of diagnosis and treatment, and economic consequences. The demographics of this group were similar to those in smaller treatment-seeking clinical samples, but not necessarily to OCD sufferers within the US population as a whole. More than half of the patients reported moderate to severe interference in family relationships, socializing, and ability to study or work, secondary to OCD symptoms. A 10.2-year gap was observed between the onset of symptoms and the first attempt to seek professional help, and a 17.2-year gap was observed between the onset of symptoms and receipt of effective treatment. Specific treatments, such as serotonin reuptake inhibitors and behavior therapy, showed greater symptom improvement, and significantly reduced the total annual fees incurred by OCD patients when compared with nonspecific treatments.

Our study results indicate that OCD has a profound effect on psychosocial functioning and quality of life. Large direct costs for OCD and even larger indirect costs due to lost wages and underemployment were found. Greater awareness of OCD among practitioners may result in earlier diagnosis and more appropriate and cost-effective treatments.

Various theories exist concerning the philosophical, biopsychosocial, and anatomic aspects of obsessive-compulsive disorder (OCD). The heterogeneous symptomatology of OCD and the complex interaction between the brain as a physical structure and the mind demands a theory fo OCD that recognizes the disorder as a unified emergent property. A unified theory of OCD is proposed, which incorporates the neurochemical, neuroanatomic, and psychatric underpinnings of this disorder, explor the methods by which OCD pathologies impact the neuroanatomic circuits of the brain, and explains how, through its symptmatology, OCD is “communicated” by the mind to the outside world.

Several lines of evidence suggest that the neuropeptide oxytocin (OT) may be involved in the pathophysiology of obsessive-compulsive behavior in humans and repetitive grooming behavior in animals. Trichotillomania (TTM), which is characterized by chronic hair pulling, may be conceptualized as a disorder of pathologic grooming. To investigate the role of OT in TTM, the cerebrospinal fluid (CSF) levels of OT in nine women with TTM and nine healthy female controls were measured. Early findings from this ongoing study fail to demonstrate a significant difference in CSF OT levels between women with TTM and healthy female controls.

Pathological gambling is an understudied disorder that causes significant distress to sufferers, their families, and society. Despite its prevalence among the general population, the impact of pathological gambling remains largely unrecognized by many health care providers. Although a discrete entity, pathological gambling shares salient characteristics with addiction and obsessive-compulsive disoders, and is comorbid with these and other conditions such as attention-deficit hyperactivity disorder in a large number of cases. Recognizing these similarities has significant implications for treatment, as pharmacologic therapies used for these disorders, including serotonergic and mood-stabilizing agents, have shown some degree of efficacy in pathological gambling.

In Washington these days, there is no shortage of people willing to dispense advice about what clinicians can do to impact national mental health policy. The advice and comments that follow reflect one perspective, but it is not that of a psychiatrist, a psychopharmacologist, a nurse, a social worker, or a member of any medical profession. Rather, it is the view of one of the legions of Washington bureaucrats with fancy titles and delusions of grandeur. The difference is that this view happens to have a chemical basis—it comes from a person with a decade of experience dealing firsthand with both manic-depressive illness and mental health policy.

In this article, we discuss the use of venlafaxine, an antidepressant with predominant effects at both noradrenergic and serotonergic reuptake sites, in the treatment of trichotillomania (TTM), a complex psychiatric condition manifested by chronic, severe hair pulling. We review case examples of 10 consecutive patients exhibiting moderately severe TTM symptoms, as judged by self-report, extent of hair loss, and duration of remission, and discuss our observations regarding the effects of venlafaxine therapy (mean dose, 274 mg/day) on these patients over the course of several months (mean, 15.1 weeks). The Massachusetts General Hospital Hair Pulling Scale, Massachusetts General Hospital Trichotillomania Impact Scale (MGH TIS), Psychiatric Institute Trichotillomania Scale (PITS), Beck Depression Inventory (BDI), Beck Anxiety Inventory (BAI), and Clinical Global Improvement (CGI) scale were used to appraise the patients' condition during routine clinical visits. A retrospective chart review of clinical data demonstrated significant improvement in TTM symptoms from baseline to last clinical visit in both behavioral (MGH HPS, P=.02; PITS, P=.02) and psychosocial (MGH TIS, P=.009) terms. Mean improvement on the CGI scale was 2.38±1.51, between “much improved” (2) and “slightly improved” (3). There were no significant differences from baseline to endpoint scores on the BDI or BAI. This retrospective treatment review indicates that short-term treatment with venlafaxine improved TTM symptoms; however, longer controlled trials with extended baseline periods are needed for optimal assessment of pharmacologic treatment of TTM. We look to future studies to confirm and supplement our initial positive findings.